Search

Displaying results 1071 - 1080 of 10000 in total
  1. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors.

  2. Drug

    Brompheniramine

    go.drugbank.com/drugs/DB00835
    Approved

    Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

    Mixtures: Up and Up Childrens Cold and Cough, Phenylephrine ComplexCategories: Antihistamines for Systemic Use
  3. Drug

    Alnus rhombifolia pollen

    go.drugbank.com/drugs/DB10722
    Approved

    Alnus rhombifolia pollen is the pollen of the Alnus rhombifolia plant. Alnus rhombifolia pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS331657, Treatment Set TS333743
  4. Drug

    Ethoxzolamide

    go.drugbank.com/drugs/DB00311
    ApprovedWithdrawn

    Ethoxzolamide is a sulfonamide used as diuretic and in glaucoma. It inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate.

    Categories: Genito Urinary System and Sex Hormones
  5. Drug

    Quercus virginiana pollen

    go.drugbank.com/drugs/DB10375
    Approved

    Quercus virginiana pollen is the pollen of the Quercus virginiana plant. Quercus virginiana pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS340826, Treatment Set TS343826
  6. Drug

    Flavin mononucleotide

    go.drugbank.com/drugs/DB03247
    ApprovedInvestigational

    [L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on … is found.

    Mixtures: Vitamin B-Complex, Vitamin B ComplexCategories: Vitamin B Complex
  7. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. … [A232955, A232960] In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease

  8. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020,[L22619] the FDA fully approved … the use of baricitinib for the treatment of COVID-19 in May 2022.

  9. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    It is being developed by Acologix, Inc. … AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).

  10. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane. … Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group.